GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Pharma Holding Inc (STU:XQJ0) » Definitions » Debt-to-Revenue

China Pharma Holding (STU:XQJ0) Debt-to-Revenue : 0.76 (As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is China Pharma Holding Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

China Pharma Holding's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €2.52 Mil. China Pharma Holding's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €1.32 Mil. China Pharma Holding's annualized Revenue for the quarter that ended in Mar. 2024 was €5.04 Mil. China Pharma Holding's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.76.


China Pharma Holding Debt-to-Revenue Historical Data

The historical data trend for China Pharma Holding's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Pharma Holding Debt-to-Revenue Chart

China Pharma Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.61 0.68 1.30 1.08 0.66

China Pharma Holding Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.10 1.77 0.75 0.54 0.76

Competitive Comparison of China Pharma Holding's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, China Pharma Holding's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Pharma Holding's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Pharma Holding's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where China Pharma Holding's Debt-to-Revenue falls into.



China Pharma Holding Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

China Pharma Holding's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.918 + 1.331) / 6.429
=0.66

China Pharma Holding's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.517 + 1.315) / 5.04
=0.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


China Pharma Holding Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of China Pharma Holding's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


China Pharma Holding (STU:XQJ0) Business Description

Traded in Other Exchanges
Address
Second Floor, No. 17, Jinpan Road, Hainan Province, Haikou, CHN, 570216
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.

China Pharma Holding (STU:XQJ0) Headlines

No Headlines